Home / Peptides / PT-141
FDA-Approved (Vyleesi)

PT-141 — Bremelanotide / Vyleesi

Sexual Dysfunction. PT-141 (bremelanotide) is a synthetic peptide analog of α-MSH that acts on the melanocortin receptor system. Unlike PDE5...

Sequence
Cyclic Heptapeptide
Category
FDA-Approved (Vyleesi)
Primary Use
Sexual Dysfunction
Administration
SubQ

What Is PT-141?

PT-141 (bremelanotide) is a synthetic peptide analog of α-MSH that acts on the melanocortin receptor system. Unlike PDE5 inhibitors (Viagra, Cialis) which work on the vascular system, PT-141 works through the central nervous system to increase sexual desire. FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.

sexual health melanocortin HSDD FDA-approved

Mechanism of Action

PT-141 activates melanocortin-4 receptors (MC4R) in the hypothalamus, targeting desire and arousal at the neurological level rather than facilitating blood flow. Originally derived from Melanotan II, it was developed to isolate pro-sexual effects without tanning side effects.

Key Research Findings

  • Female HSDD — Phase III (RECONNECT) showed significant increases in sexual desire and reduced distress in premenopausal women
  • Male ED — Phase II efficacy in men with ED, including PDE5 inhibitor non-responders (not FDA-approved for this)
  • Central mechanism — Neuroimaging confirms activation of brain regions associated with sexual arousal
  • Rapid onset — Effects typically observed within 45 minutes of SubQ administration

Important: The evidence base for PT-141 varies by application. Many findings are from preclinical (animal or in vitro) studies. Large-scale human clinical trials may not be completed. Always evaluate the quality of evidence before drawing conclusions.

Known Side Effects

Nausea is the most common effect (~40% of trial participants). Other effects include flushing, headache, injection site reactions, and transient BP increases. FDA label warns of hyperpigmentation risk with repeated use. Limited to once per 24 hours, max 8 doses/month.

Legal Status (2026)

PT-141 (bremelanotide) is FDA-approved as Vyleesi for HSDD in premenopausal women. Off-label use requires a prescription. Available from compounding pharmacies and research suppliers.

Where to Buy PT-141 for Research

These verified suppliers carry PT-141 with third-party COAs and US-based shipping.

BP
BioPure Peptides
USA-made · 99%+ purity · WHO/GMP certified
  • Third-party tested with COAs on every batch
  • Ships from Chandler, AZ — free shipping over $200
  • 30+ peptides in catalog including blends and stacks
Shop BioPure Peptides →
Affiliate Disclosure: PeptideOnline may earn a commission on purchases made through these links. This does not influence our editorial content. Full disclosure →